GeneDx Holdings Corp. (WGS NASDAQ) stock market data APIs
$119.9766
1.66(1.4%)
as of October 22, 2025
Try our APIs with
free plan!
GeneDx Holdings Corp. Financial Data Overview
Price chart is built with
Anychart
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Prev. Close
119.9766
Open
121.6394
High
124.7653
Low
116.3898
52 wk Range
55.17-136
Market Cap
3 476 M
P/E Ratio
1512.625
Shares Outstanding
28 726 K
Revenue
362 M
EPS
0.5
Beta
2.042
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GeneDx Holdings Corp. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GeneDx Holdings Corp. data using free add-ons & libraries
Get GeneDx Holdings Corp. Fundamental Data
GeneDx Holdings Corp. Fundamental data includes:
- Net Revenue: 362 M
- EBITDA: 29 595 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-28
- EPS/Forecast: 0.118
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GeneDx Holdings Corp. News
New
Four Reasons To Watch This 'Breakthrough' Stock — Including 954% Expected Growth
Earning an FDA Breakthrough Device Designation, GeneDx stock targets a breakout ahead of earnings — and expectations of 954% growth. Continue Reading View Comments
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025
Data from more than 22,000 newborns reinforce GeneDx’s role spearheading the adoption of genomic newborn screening (gNBS) from research to clinical practice GAITHERSBURG, Md., October 22, 2025--(BU...
3 Stocks Estimated To Be Undervalued In October 2025
As the Dow Jones Industrial Average reaches an all-time high amidst a flurry of corporate earnings reports, investors are keenly observing the broader U.S. market's performance against a backdrop of o...
Uncovering 3 Stocks Including Palo Alto Networks That May Be Trading Below Intrinsic Value Estimates
As the U.S. stock market begins the week on a high note, buoyed by gains across major indices and ongoing developments in trade and inflation data, investors are keenly observing opportunities amid ec...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
